NOVO NORDISK A S
Business
Novo Nordisk A/S is a global healthcare company that discovers, develops, manufactures and markets pharmaceutical products primarily focused on obesity and diabetes care and treatments for certain rare diseases. It offers prescription medicines including GLP-1 receptor agonists for obesity and diabetes, modern and human insulins, growth hormone and haemophilia therapies, and related delivery devices and services. The company operates through two principal business segments—Obesity and Diabetes care and Rare disease. Novo Nordisk markets its products worldwide through subsidiaries, distributors and independent agents across major regions including the United States, China, Europe and other international markets.
Summary from filing dated 2026-02-04
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $102.43B |
| Total assets | $542.90B |
| Total liabilities | $348.86B |
| Stockholders' equity | — |
| Operating cash flow | — |